BlueRock Therapeutics, a Bayer subsidiary developing stem cell treatments for Parkinson’s disease, has partnered with Rune Labs to collect Apple Watch sensor data during clinical trials of its experimental cell therapy. The deal puts FDA-cleared wearable software at the center of a drug development program, giving trial investigators a continuous stream of motor symptom data that periodic clinic visits cannot replicate. If the approach works, it could reshape how drugmakers measure whether their therapies actually help patients between scheduled assessments.
What the Partnership Involves
BlueRock will integrate Rune Labs’ StriveStudy platform into trials of bemdaneprocel, also known as BRT-DA01, an investigational therapy that implants lab-grown dopamine neurons into the brains of Parkinson’s patients. The goal is to use the platform to better characterize disease state across the full arc of a trial rather than relying solely on snapshots taken during office visits. StriveStudy runs on Apple Watches equipped with NeuroRPM, software that uses the device’s built-in accelerometer and gyroscope to track movement patterns around the clock.
The partnership is designed to support subsequent trials of bemdaneprocel, meaning the wearable data layer is not a one-off pilot but a planned component of BlueRock’s broader clinical program. That distinction matters because it signals the company views continuous digital measurement as essential to proving its therapy works, not merely as a supplementary data source. For Rune Labs, it embeds its platform deeper into interventional research rather than just observational monitoring, potentially setting a template for how other neurology trials might be instrumented.
How Apple Watch Sensors Track Motor Symptoms
Parkinson’s disease produces motor fluctuations that shift throughout the day. A patient might experience severe tremor in the morning, relative calm at midday, and involuntary movements called dyskinesia by evening. Traditional trial endpoints rely on clinician-rated scales administered during brief appointments, which can miss these swings entirely and are vulnerable to subjective variation between raters.
Peer-reviewed research published in Science Translational Medicine demonstrated that smartwatch inertial sensors can continuously monitor real-world motor fluctuations, including tremor and dyskinesia, outside controlled clinical settings. The study established a framework for transforming raw accelerometer and gyroscope signals into standardized symptom scores, which underpins the Apple Watch monitoring ecosystem now being applied in BlueRock’s program. By converting movement data into time-stamped estimates of symptom severity, the system produces a record of how a patient actually moves during daily life, not just how they appear in the exam room.
This continuous data stream addresses a well-known blind spot in Parkinson’s trials. A patient who happens to feel relatively well during a clinic visit may appear to be responding to treatment even if symptoms are severe the rest of the week. Conversely, someone having a bad day at the clinic could look like a non-responder despite meaningful improvement at home. Wearable monitoring reduces the role of timing luck in trial results and can help distinguish true treatment effects from day-to-day variability.
NeuroRPM’s Regulatory Standing
The software powering this monitoring, NeuroRPM, is not an unregulated wellness app. It holds FDA 510(k) clearance under entry K221772, meaning the agency reviewed it as a medical device and determined it is substantially equivalent to a legally marketed predicate. That clearance gives BlueRock a regulatory foothold: data collected through NeuroRPM carries more weight with regulators than readings from consumer fitness trackers that lack formal review and performance benchmarks.
The clearance also reflects a broader shift at federal health agencies toward accepting digital health tools in clinical evidence packages. For drugmakers, using cleared software reduces the risk that regulators will later question the validity of wearable-derived endpoints. For patients enrolled in trials, it means the data shaping treatment decisions has passed a defined quality threshold overseen by the U.S. health department, including requirements around safety, reliability, and intended use.
Why Cell Therapy Trials Need Better Measurement
Bemdaneprocel is not a pill taken daily. It is a one-time surgical implantation of pluripotent stem cell-derived dopamine neurons, designed to replace the cells that Parkinson’s disease destroys. The therapy’s effects, if they materialize, would unfold over months or years as transplanted cells integrate into the brain’s circuitry and begin to modulate motor pathways. That timeline creates a measurement problem: standard rating scales administered every few weeks may not detect gradual, incremental improvement that accumulates slowly and unevenly.
Continuous wearable monitoring is better suited to this kind of therapy because it generates dense longitudinal data. Instead of asking whether a patient improved between Visit 3 and Visit 4, investigators can examine daily and weekly trends, identify when motor function began to shift, and correlate those changes with biological milestones in cell engraftment. The Science Translational Medicine work on smartwatch-based Parkinson’s assessment specifically highlighted the ability to capture fluctuations that traditional assessments miss, a capability that becomes more valuable when the expected treatment effect is slow and subtle.
BlueRock’s decision to build wearable data into its trial infrastructure also reflects a practical calculation about sample size and statistical power. If digital endpoints reduce measurement noise by averaging many days of data, the company may need fewer patients to detect a statistically significant treatment effect. Smaller, more efficient trials cost less and can reach results faster, a meaningful advantage for a therapy that requires neurosurgery and carries inherent enrollment challenges related to risk, travel, and follow-up intensity.
Limits of the Current Approach
The partnership announcement, distributed through a press service, describes StriveStudy as capturing “a holistic picture” of a patient’s disease state. That framing deserves scrutiny. Apple Watch sensors measure limb movement effectively, but they do not directly assess non-motor symptoms such as sleep disturbances, mood changes, cognitive decline, or autonomic dysfunction, all of which weigh heavily on quality of life in Parkinson’s disease.
Even on the motor side, wrist-worn devices have blind spots. Gait changes, freezing episodes, and balance issues may be only partially captured if a patient is not moving their arms in a typical pattern. Calibration and algorithm performance can vary across individuals, and environmental factors or concurrent conditions may influence readings. Continuous data can also introduce new analytical complexities: separating meaningful trends from noise requires careful statistical modeling and pre-specified analysis plans.
There are logistical and equity concerns as well. Relying on Apple Watch hardware assumes patients are comfortable wearing and charging a device every day and that they can navigate basic technology tasks. Trial teams must manage device provisioning, technical support, and data connectivity. If future implementations depend on participants using their own consumer devices, differences in hardware generations and operating systems could further complicate standardization.
From a privacy perspective, continuous monitoring generates large volumes of sensitive behavioral data. While clinical trials already involve strict confidentiality safeguards, adding wearable streams raises questions about who can access raw data, how long it is stored, and whether it might eventually be reused beyond the original trial context. Those questions become more pointed when the data is collected via commercial platforms rather than bespoke research hardware.
What It Means for Digital Endpoints in Drug Development
Despite these limitations, the BlueRock-Rune Labs collaboration is notable because it embeds a cleared digital measure into a cutting-edge cell therapy program rather than treating wearables as an optional add-on. If the approach proves feasible and the data aligns with traditional endpoints, it could encourage more sponsors to structure trials around continuous measurement, particularly in disorders marked by fluctuating symptoms.
For regulators, the project offers another test case in how to evaluate digital endpoints alongside established clinical scales. Demonstrating that smartwatch-derived metrics correlate with meaningful changes in daily function will be critical if companies hope to use them as primary or key secondary endpoints in pivotal studies. For now, the technology is more likely to complement than replace standard assessments, helping to explain why some patients respond better than others and informing the design of subsequent trials.
The partnership also underscores how clinical research infrastructure is evolving. Sponsors are increasingly turning to specialized platforms rather than building their own digital tools from scratch, and services like corporate news distribution are being used to signal these strategic bets to investors and potential collaborators. As more evidence accumulates from programs like BlueRock’s, the question may shift from whether to use continuous monitoring to how best to integrate it into trial design, patient experience, and regulatory strategy.
For now, the BlueRock-Rune Labs effort remains an experiment in marrying advanced cell therapy with real-world digital measurement. Its outcome will help determine whether smartwatch data becomes a routine part of how future Parkinson’s treatments are tested, and ultimately, how their benefits and limits are understood.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
